Affordable Access

deepdyve-link
Publisher Website

Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects.

Authors
  • McColm, Juliet1
  • Brittain, Claire1
  • Suriyapperuma, Subha1
  • Swanson, Steven2
  • Tauscher-Wisniewski, Sitra2
  • Foster, Joanne1
  • Soon, Danny3
  • Jackson, Kimberley1
  • 1 Eli Lilly and Company, Windlesham, UK.
  • 2 Eli Lilly and Company, Indianapolis, Indiana, USA. , (India)
  • 3 Lilly-NUS Centre for Clinical Pharmacology, Singapore. , (Singapore)
Type
Published Article
Journal
British Journal of Clinical Pharmacology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Aug 01, 2017
Volume
83
Issue
8
Pages
1654–1667
Identifiers
DOI: 10.1111/bcp.13252
PMID: 28156011
Source
Medline
Keywords
License
Unknown

Abstract

Oral doses of LY2979165 up to 60 mg as a single dose and up to 400 mg given as multiple QD doses, using a titration regimen, were well tolerated with linear PK. Overall, these data support further clinical evaluation of LY2979165.

Report this publication

Statistics

Seen <100 times